Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety Assessment of a Subcutaneous Immunotherapy (Beltavac®) With Polymerized Allergenic Extract From House Dust Mites in Patients With Allergic Rhinitis/Rhinoconjuntivitis

NCT05395689 is registered in ClinicalTrials.gov with Probelte Pharma S.L.U. as lead sponsor.

NCT NCT05395689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05395689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety Assessment of a Subcutaneous Immunotherapy (Beltavac®) With Polymerized Allergenic Extract From House Dust Mites in Patients With Allergic Rhinitis/Rhinoconjuntivitis
Lead sponsor
Probelte Pharma S.L.U.
Phase
Phase 3
Overall status
Unknown status
Start date
January 17, 2022
Completion date
June 30, 2026
Enrollment
350 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

house dust mite allergy